Kairos Pharma, Ltd.
KAPA
$0.96
$0.05265.80%
AMEX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -313.83% | 21.67% | 71.11% | -258.33% | -32.20% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | 505.26% | -5.00% | -23.08% | 160.00% | 0.00% |
| Total Other Non-Cash Items | -- | -- | -- | -- | -- |
| Change in Net Operating Assets | -6,634.62% | -91.30% | 45.85% | -41.93% | 199.15% |
| Cash from Operations | -1,102.38% | -566.67% | -45.45% | -27.47% | 233.82% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -60.78% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -840.43% | 152.81% | -23.61% | 67.86% | -292.98% |
| Cash from Financing | 3,400.67% | 267.42% | -23.61% | 67.86% | -292.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 16,921.05% | 64.15% | -783.33% | 95.49% | -6.40% |